Effects of Biological Response Modifiers with Different Modes of Action Used Separately and Together on Immune Responses in Mice with Syngeneic Tumours

Abstract

The effect of a protein-bound polysaccharide (PSK) obtained from cultured mycelia of the Basidiomycetes Coriolus versicolor on activities involved in the host defence mechanism of C57BL/6 mice bearing adenocarcinoma 755 was compared with that of live bacille Calmette-Guérin (BCG). Delayed footpad reaction, the activity of splenic natural killer cells and interferon production induced by concanavalin A in splenic cells of healthy mice were little affected by PSK, but in mice bearing tumours PSK prevented the tumour-induced reduction in these activities. Live BCG augmented these activities in healthy mice but had little effect on the reduction of activities induced by a tumour. The immunosuppressive activity of the serum of tumour-bearing mice was reduced by PSK administration; live BCG did not have this effect. The combined use of live BCG and PSK improved these activities in the host, with synergistic increases in the antitumour effect. These results suggest that the combined use of live BCG and PSK, which have different modes of action, may be useful in the treatment of cancer.

Keywords

PROTEIN-BOUND POLYSACCHARIDE (PSK)LIVE BACILLE CALMETTE-GUÉRIN HOST DEFENCE MECHANISM TUMOUR-BEARING MICE

Get full access to this article

View all access options for this article.

References

Tsukagoshi

Hashimoto

Fujii

Krestin (PSK). Cancer Treat Rev 1984; 11: 131–155.

Mitomi

Tsuchiaya

Iijima

Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992; 35: 123–155.

Kondo

Torisu

Evaluation of anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Basic Mechanisms in Clinical Treatment of Tumor Metastasis ( Yoshida

ed.). Orlando: Academic Press, 1985; pp 623–636.

Torisu

Hayashi

Ishimitsu

Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990; 31: 261–268.

Hattori

Nakajima

Nakazato

Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 1990; 20: 127–136.

Yoshikumi

Nomoto

Matsunaga

Mouse strain difference in the expression of antitumor activity of PS-K. Gann 1975; 66: 649–654.

Nomoto

Yoshikumi

Matsunaga

Restoration of antibody-forming capacities by PS-K in tumour-bearing mouse. Gann 1975; 66: 365–374.

Matsunaga

Morita

Oguchi

Restoration of immune responsiveness by a biological response modifier, PSK, in aged mice bearing syngeneic transplantable tumor. J Clin Lab Immunol 1987; 24: 143–149.

Matsunaga

Morita

Iijima

Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumour-bearing hosts. J Clin Lab Immunol 1990; 31: 127–136.

10.

Yoshikai

Miyake

Matsumoto

Effect of stimulation and blockade of mononuclear phagocyte system on the delayed footpad reaction to SRBC. Immunology 1979; 38: 577–582.

11.

de Jong

Steerenberg

Ruitenberg

Bacillus Calmette-Guérin (BCG) and its use for cancer immunotherapy. Res Monogr Immunol 1981; 11: 283–300.

12.

Herr

Whitemore

Jr Urethral carcinoma in situ after successful intravesical therapy for superficial bladder tumours: incidence, possible pathogenesis and management. J Urol 1987; 138: 138–142.

13.

Meijden

APM

Steerenberg

Hoogstraaten

IMW

Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with Bacillus Calmette-Guérin. Cancer Immunol Immunother 1989; 28: 287–295.

14.

Geffard

Orback-ArBouys

Enhancement of T-suppressor activity in mice by high doses of BCG. Cancer Immunol Immunother 1976; 1: 41–45.

15.

Bennett

Rao

Mitchell

Systemic Bacillus Calmette-Guérin (BCG) activates natural suppressor cells. Proc Natl Acad Sci USA 1978; 75: 5152–5157.

16.

Varesio

Biasi

Thurman

Potent activation of mouse macrophages by recombinant interferon-γ. Cancer Res 1984; 44: 4465–4469.

17.

Sayers

Mason

Ortaldo

Regulation of human natural killer cell activity by interferon-γ: lack of a role in interleukin-2-mediated augmentation. J Immunol 1986; 136: 2176–2180.

18.

Cameron

McIntosh

Rosenberg

Synergistic antitumour effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastasis. Cancer Res 1988; 48: 5810–5817.

19.

Iigo

Sakurai

Tamura

In vivo antitumour activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48: 260–264.

20.

Wada

Okamura

Nagata

Cellular mechanism in in vivo production of gamma interferon induced by lipopolysaccharide in mice infected with Mycobacterium bovis BCG. J Interferon Res 1985; 5: 431–440.